Back to results
US 2006/0233758 A1Published application
Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
OwnerPierre-Francois Tosi, Claudie Madoulet +2inventors
InventorsPierre-Francois Tosi, Claudie Madoulet, Claude Nicolau, David Hickman
Life of this patent
Estimating the term…
Abstract
The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
Claims5
A conjugate comprising
- at least one peptide based on or derived from an extracellular loop of a P-glycoprotein, said peptide having an N- and C-terminal end,
- one or more terminal amino acids attached to said N- and C-terminal end of said peptide,
- at least two spacer molecules each having two termini,
- a first of said termini being covalently attached to a phospholipid, and
- a second of said termini being covalently attached to one of said terminal amino acids.
2 more elements
A conjugate comprising
- at least one peptide comprising
- (a) at least 10 amino acid residues of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 7, SEQ ID No. 11, SEQ ID No. 13;
- or
- (b) at least 10 amino acid residues providing a peptide with a number of amino acid residues, wherein said peptide has at least 60% sequence identity with a number of consecutive amino acids residues of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 7, SEQ ID No. 11, SEQ ID No. 13 that corresponds to the number of amino acid residues of said peptide;
- said peptide having an N- and C-terminal end,
- one or more terminal amino acids attached to said N- and C-terminal end of said peptide,
- at least two spacer molecules each having two termini,
- a first of said termini being covalently attached to a phospholipid, and
- a second of said termini being covalently attached to one of said terminal amino acids.
6 more elements
5-45. (canceled)
Dependencies are inferred from the claim text.